News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2018 Shelley Wood November 30, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018